{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:32:40Z","timestamp":1786696360385,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.talanta.2026.130083","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:23:13Z","timestamp":1780935793000},"page":"130083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Isocratic zwitterionic HILIC\u2013ESI\u2013MS method for assay of ropinirole and quantitation of degradation impurities in extended-release tablets"],"prefix":"10.1016","volume":"310","author":[{"given":"Vasiliki","family":"Brakoulia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-6690","authenticated-orcid":false,"given":"Ariadni","family":"Geballa-Koukoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bogeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kakouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-0127","authenticated-orcid":false,"given":"Irene","family":"Panderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2026.130083_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson's disease and parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"10.1016\/j.talanta.2026.130083_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0091-3057(91)90603-Y","article-title":"Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist","volume":"38","author":"Eden","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.talanta.2026.130083_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1527-3458.2005.tb00046.x","article-title":"Ropinirole, a non-ergoline dopamine agonist","volume":"11","author":"Jost","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.talanta.2026.130083_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2047-9158-1-10","article-title":"Drug therapy in patients with Parkinson's disease","volume":"1","author":"M\u00fcller","year":"2012","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.talanta.2026.130083_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mds.1149","article-title":"Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)","volume":"16","author":"Maratos","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.talanta.2026.130083_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.talanta.2026.130083_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/004982599238696","article-title":"Disposition of ropinirole in animals and man","volume":"29","author":"Ramji","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.talanta.2026.130083_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00702-024-02828-5","article-title":"Therapeutic drug monitoring in Parkinson's disease","volume":"131","author":"M\u00fcller","year":"2024","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.talanta.2026.130083_bib10","unstructured":"United States Pharmacopeial Convention, Ropinirole extended-release tablets, Revision Bulletin, Posting date 28 Jun 2019, Official date 01 Jul 2019, USPC, Rockville, MD, USA. https:\/\/www.uspnf.com\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/ropirinole-ert-rb-20190628.pdf (accessed March 1, 2026)."},{"key":"10.1016\/j.talanta.2026.130083_bib11","series-title":"Ropinirole Hydrochloride, EP 10.0","first-page":"3742","year":"2020"},{"key":"10.1016\/j.talanta.2026.130083_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2013.07.013","article-title":"Forced degradation and impurity profiling: recent trends in analytical perspectives","volume":"86","author":"Jain","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.talanta.2018.02.068","article-title":"Development and validation of a hydrophilic interaction liquid chromatography method for the quantitation of impurities in fixed-dose combination tablets containing rosuvastatin and metformin","volume":"183","author":"Machairas","year":"2018","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130083_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpba.2016.04.038","article-title":"A simple and sensitive method to analyze genotoxic impurity hydrazine in pharmaceutical materials","volume":"126","author":"Wang","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408347.2025.2586047","article-title":"Exploring the pharmaceutical significance and analytical landscape of ropinirole: an in-depth review of an indole-based dopaminergic therapeutic agent","author":"Pawara","year":"2025","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib17","first-page":"617","article-title":"A new HPLC method for determination of ropinirole in human plasma and its application in bioequivalence studies","volume":"8","author":"Khan","year":"2017","journal-title":"Biosci. Biotechnol. Res. Asia"},{"key":"10.1016\/j.talanta.2026.130083_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/bmc.1144","article-title":"Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg\/mL in human plasma by LC-ESI-MS\/MS: application to a clinical pharmacokinetic study","volume":"23","author":"Bharathi","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.talanta.2026.130083_bib19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jpba.2005.09.024","article-title":"Rapid and sensitive liquid chromatography\u2013mass spectrometry method for determination of ropinirole in human plasma","volume":"40","author":"Bhatt","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpba.2006.08.001","article-title":"The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers","volume":"43","author":"Wen","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jchromb.2016.02.041","article-title":"Validated UHPLC\u2013MS\/MS method for the simultaneous determination of pramipexole and ropinirole in plasma of patients with Parkinson's disease","volume":"1017","author":"Mohamed","year":"2016","journal-title":"J. Chromatogr., B"},{"key":"10.1016\/j.talanta.2026.130083_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2018.11.007","article-title":"Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease","volume":"61","author":"Contin","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.talanta.2026.130083_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-024-12870-8","article-title":"Impulse control and correlation to dopamine agonist serum concentrations in people with Parkinson's disease","volume":"272","author":"Staubo","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.talanta.2026.130083_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.111151","article-title":"Ropinirole metabolite mimics a new psychoactive substance (4-HO-MET) in LC-MS\/MS","volume":"331","author":"Tang","year":"2022","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.talanta.2026.130083_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1365\/s10337-008-0866-1","article-title":"Forced degradation study to develop and validate stability-indicating RP-LC for quantification of ropinirole hydrochloride in its modified release tablets","volume":"69","author":"Parmar","year":"2009","journal-title":"Chromatographia"},{"key":"10.1016\/j.talanta.2026.130083_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1365\/s10337-006-0045-1","article-title":"Method development and validation of a rapid determination of ropinirole in tablets by LC-UV","volume":"64","author":"\u00d6nal","year":"2006","journal-title":"Chromatographia"},{"key":"10.1016\/j.talanta.2026.130083_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2015.06.035","article-title":"HPLC-UV method development and validation for the quantification of ropinirole in new PLGA multiparticulate systems: microspheres and nanoparticles","volume":"491","author":"Fuster","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.talanta.2026.130083_bib28","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1002\/jssc.201900458","article-title":"Application of chemometric approach for development and validation of high-performance liquid chromatography method for estimation of ropinirole","volume":"42","author":"Fatima","year":"2019","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.talanta.2026.130083_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0021-9673(95)00766-0","article-title":"Determination of liquid chromatographic peak purity by electrospray ionization mass spectrometry","volume":"721","author":"Bryant","year":"1996","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2026.130083_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0378-4347(98)00427-7","article-title":"Determination of the dissociation constants of ropinirole and some impurities and their quantification using capillary zone electrophoresis","volume":"720","author":"Coufal","year":"1998","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2026.130083_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0378-4347(99)00314-X","article-title":"Separation and quantification of ropinirole and some impurities using capillary liquid chromatography","volume":"732","author":"Coufal","year":"1999","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.talanta.2026.130083_bib32","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1080\/10826076.2013.850720","article-title":"Impurity profiling of the ropinirole extended-release formulation, identification and characterization of potential degradant","volume":"37","author":"Reddy","year":"2014","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.talanta.2026.130083_bib33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10337-013-2617-1","article-title":"Simultaneous determination of impurities in ropinirole tablets by an improved HPLC method coupled with diode array detection","volume":"77","author":"Kakouris","year":"2014","journal-title":"Chromatographia"},{"key":"10.1016\/j.talanta.2026.130083_bib34","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3390\/molecules25112691","article-title":"Developing an improved UHPLC method for efficient determination of European Pharmacopoeia process-related impurities in ropinirole hydrochloride using analytical quality by design principles","volume":"25","author":"Tome","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.talanta.2026.130083_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.chroma.2008.10.059","article-title":"Chemometrical evaluation of ropinirole and its impurity's chromatographic behavior","volume":"1216","author":"Jancic-Stojanovic","year":"2009","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.talanta.2026.130083_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.talanta.2014.02.006","article-title":"The influence of inorganic salts with chaotropic properties on the chromatographic behavior of ropinirole and its two impurities","volume":"123","author":"Vemi\u0107","year":"2014","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2026.130083_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0731-7085(97)00235-5","article-title":"Comparison of LC detection methods in the investigation of non-UV detectable organic impurities in a drug substance","volume":"17","author":"McCrossen","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0731-7085(97)00132-5","article-title":"Active drug substance impurity profiling: part II. LC\/MS\/MS fingerprinting","volume":"16","author":"Nicolas","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib39","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/jssc.200700630","article-title":"The advantages of ESI-MS detection in conjunction with HILIC mode separations: fundamentals and applications","volume":"31","author":"Nguyen","year":"2008","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.talanta.2026.130083_bib40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00216-011-5308-5","article-title":"Hydrophilic interaction liquid chromatography (HILIC)-a powerful separation technique","volume":"402","author":"Buszewski","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib41","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.chroma.2010.03.011","article-title":"Study of the selectivity, retention mechanisms and performance of alternative silica-based stationary phases for separation of ionised solutes in hydrophilic interaction chromatography","volume":"1217","author":"McCalley","year":"2010","journal-title":"J. Chromatogr., A"},{"key":"10.1016\/j.talanta.2026.130083_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.aca.2017.01.060","article-title":"Recent advances in stationary phases and understanding of retention in hydrophilic interaction chromatography. A review","volume":"967","author":"Jandera","year":"2017","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.talanta.2026.130083_bib43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10337-016-3119-8","article-title":"Investigation of the retention mechanism of cephalosporins by zwitterionic hydrophilic interaction liquid chromatography","volume":"79","author":"Panderi","year":"2016","journal-title":"Chromatographia"},{"key":"10.1016\/j.talanta.2026.130083_bib44","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jpba.2006.11.030","article-title":"Isolation and characterization of some potential impurities in ropinirole hydrochloride","volume":"43","author":"Sahasrabuddhey","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.talanta.2026.130083_bib45","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/jhet.5570320334","article-title":"Some synthetic approaches to ropinirole (SK&F 101468-A): a potent dopamine receptor agonist","volume":"32","author":"Hayler","year":"1995","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib46","author":"Koftis"},{"key":"10.1016\/j.talanta.2026.130083_bib47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trac.2013.04.010","article-title":"The 12 principles of green analytical chemistry and the significance mnemonic of green analytical practices","volume":"50","author":"Ga\u0142uszka","year":"2013","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2021.116223","article-title":"White analytical chemistry: an approach to reconcile the principles of green analytical chemistry and functionality","volume":"138","author":"Nowak","year":"2021","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib49","article-title":"Q2(R2) validation of analytical procedures","year":"2023","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.talanta.2026.130083_bib50","unstructured":"Stat-Ease, Inc., Design-Expert, Version 25.0.5 [software], Minneapolis, MN, USA."},{"key":"10.1016\/j.talanta.2026.130083_bib51","unstructured":"Advanced Pharma Algorithms, Inc., ADME Boxes, Version 3.0 [software], Toronto, Canada."},{"key":"10.1016\/j.talanta.2026.130083_bib52","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use, Annex I, as Amended."},{"key":"10.1016\/j.talanta.2026.130083_bib53","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/analytica5030030","article-title":"Modified GAPI (MoGAPI) tool and software for the assessment of method greenness: case studies and applications","volume":"5","author":"Mansour","year":"2024","journal-title":"Analytica"},{"key":"10.1016\/j.talanta.2026.130083_bib54","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1039\/D3GC02347H","article-title":"Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality","volume":"25","author":"Manousi","year":"2023","journal-title":"Green Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib55","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1039\/D4GC05298F","article-title":"Red analytical performance index (RAPI) and software: the missing tool for assessing methods in terms of analytical performance","volume":"27","author":"Nowak","year":"2025","journal-title":"Green Chem."},{"key":"10.1016\/j.talanta.2026.130083_bib56","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1021\/acs.analchem.5c00212","article-title":"Violet innovation grade index (VIGI): a new survey-based metric for evaluating innovation in analytical methods","volume":"97","author":"Fuente-Ballesteros","year":"2025","journal-title":"Anal. Chem."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026007393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914026007393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:17:30Z","timestamp":1786695450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914026007393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S0039914026007393"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130083","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isocratic zwitterionic HILIC\u2013ESI\u2013MS method for assay of ropinirole and quantitation of degradation impurities in extended-release tablets","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2026.130083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"130083"}}